CA 242 (tumor marker)
CA 242 is a tumor marker for sialylated Lewis carbohydrates associated with adenocarcinomas and e-selectin-mediated metastatic risk.[1][2][3]
References
- ↑ Louhimo J, Alfthan H, Stenman UH, Haglund C (2004). "Serum HCG beta and CA 72-4 are stronger prognostic factors than CEA, CA 19-9 and CA 242 in pancreatic cancer". Oncology 66 (2): 126–31. doi:10.1159/000077438. PMID 15138364.
- ↑ Haglund C, Lundin J, Kuusela P, Roberts PJ (September 1994). "CA 242, a new tumour marker for pancreatic cancer: a comparison with CA 19-9, CA 50 and CEA". Br. J. Cancer 70 (3): 487–92. doi:10.1038/bjc.1994.332. PMC 2033366. PMID 8080735.
- ↑ Röthlin MA, Joller H, Largiadèr F (February 1993). "CA 242 is a new tumor marker for pancreatic cancer". Cancer 71 (3): 701–7. doi:10.1002/1097-0142(19930201)71:3<701::AID-CNCR2820710308>3.0.CO;2-C. PMID 8431849.
|
|---|
| | Blood | |
|---|
| | Endocrine | |
|---|
| | Nervous system | |
|---|
| Cardiovascular/
respiratory | |
|---|
| | Digestive | |
|---|
| Reproductive/
urinary/
breast | |
|---|
| | General histology | |
|---|
| | Musculoskeletal | |
|---|
| |
|---|
| | Description |
- Tumor suppressing and oncogenes
- Tumor markers
- Carcinogen
|
|---|
| | Disease |
- Neoplasms and cancer
- Symptoms and signs
- Paraneoplastic
|
|---|
| | Treatment |
- Radiotherapy
- Drugs
- Immunotherapy
- intracellular chemotherapeutics
- extracellular chemotherapeutics
- adjuvant detoxification
|
|---|
|
|